<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Postmenopausal hormone (PMH) therapy may reduce <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) risk, but existing data are inconclusive </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVES: To evaluate associations between PMH therapy and incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, overall and by molecularly defined subtypes, in the population-based Iowa Women's Health Study of older women </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Exposure data were collected from Iowa Women's Health Study participants (55-69 years) at baseline (1986) </plain></SENT>
<SENT sid="3" pm="."><plain>Archived, paraffin-embedded tissue specimens for 553 CRC cases were collected and analysed to determine microsatellite instability (MSI-L/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> or MSI-H), CpG island methylator phenotype (CIMP-negative or CIMP-positive) and BRAF mutation (BRAF-<z:mp ids='MP_0002169'>wildtype</z:mp> or BRAF-mutated) status </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariable Cox regression models were fit to estimate RRs and 95% CIs </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: PMH therapy (ever vs never use) was inversely associated with incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> overall (RR=0.82; 95% CI 0.72 to 0.93), with a significantly lower risk for MSI-L/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (RR=0.75; 95% CI 0.60 to 0.94), and borderline significantly lower risks for CIMP-negative (RR=0.79; 95% CI 0.63 to 1.01) and BRAF-<z:mp ids='MP_0002169'>wildtype</z:mp> (RR=0.83; 95% CI 0.66 to 1.04) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>For PMH therapy &gt;5 years, the subtype-specific risk estimates for MSI-L/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>, CIMP-negative and BRAF-<z:mp ids='MP_0002169'>wildtype</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were: RR=0.60, 95% CI 0.40 to 0.91; RR=0.68, 95% CI 0.45 to 1.03; and RR=0.70, 95% CI 0.47 to 1.05, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>PMH therapy was not significantly associated with the MSI-H, CIMP-positive or BRAF-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> subtypes </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In this prospective cohort study, PMH therapy was inversely associated with distinct molecularly defined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> subtypes, which may be related to differential effects from <z:chebi fb="67" ids="50114">oestrogen</z:chebi> and/or <z:chebi fb="0" ids="50745">progestin</z:chebi> on <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> pathways of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>